Breaking News

Today Show Full Stories X To view all stories in expanded form, please subscribe. Get Free Trial Send Info
MRTX Mirati Therapeutics $73.01 0.82 (1.14%) 07:42 02/15/19 02/15 07:42 02/15/19 07:42 Recommendations	Mirati Therapeutics analyst commentary at H.C. Wainwright » Mirati Therapeutics price… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
MRTX Mirati Therapeutics $73.01 0.82 (1.14%) 05:07 02/15/19 02/15 05:07 02/15/19 05:07 Initiation	Mirati Therapeutics initiated at Piper Jaffray » Mirati Therapeutics… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial

Over a week ago
MRTX Mirati Therapeutics $62.51 -2.33 (-3.59%) 20:49 01/16/19 01/16 20:49 01/16/19 20:49 Syndicate	Mirati Therapeutics 1.6M share Spot Secondary priced at $62.00 » The deal priced at the… The deal priced at the top end of the $50.90-$62.00 range and was upsized to $100M from $75M. JPMorgan, Citi, Cowen, Barclays and Credit Suisse are acting as joint book running managers for the offering. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	17 Jan
CARS Cars.com $23.14 -0.26 (-1.11%) , MNKD MannKind $1.32 -0.06 (-4.35%) … 18:46 01/16/19 01/16 18:46 01/16/19 18:46 Hot Stocks	Fly Intel: After Hours Movers » HIGHER: Cars.com (CARS)… HIGHER: Cars.com (CARS) up 7.7% after announcing review of strategic alternatives... MannKind (MNKD) up 4.5% after disclosing direct purchase insulin program for Afrezza... Amicus (FOLD) up 3.5% after Citi upgrade to Buy. DOWN AFTER EARNINGS: HB Fuller (FUL) down 9.4%... Plexus Corp (PLXS) down 3.4%... CSX (CSX) down 2.1%... Kinder Morgan (KMI) down 1.7%... Alcoa (AA) down 1.6%. ALSO LOWER: Aurora Cannabis (ACB) down 7.5% after announcing convertible note offering... Mirati Therapeutics (MRTX) down 1.5% after equity offering... Apple (AAPL) down 0.2% after Bloomberg report of reduced hiring due to slow iPhone demand. Movers as of 18:30ET. CARS Cars.com $23.14 -0.26 (-1.11%) MNKD MannKind $1.32 -0.06 (-4.35%) FOLD Amicus $12.18 0.19 (1.58%) FUL H.B. Fuller $43.35 0.09 (0.21%) PLXS Plexus $54.88 1.195 (2.23%) CSX CSX $65.36 0.27 (0.41%) KMI Kinder Morgan $17.46 0.15 (0.87%) AA Alcoa $29.02 0.13 (0.45%) ACB Aurora Cannabis $7.33 0.35 (5.01%) MRTX Mirati Therapeutics $62.51 -2.33 (-3.59%) AAPL Apple $154.88 1.84 (1.20%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	16 Jan 16 Jan 16 Jan 17 Jan 17 Jan 29 Jan 29 Jan 10 Feb 11 Feb 26 Feb 27 Feb 28 May 17 Jan
MRTX Mirati Therapeutics $62.44 -2.4 (-3.70%) 16:08 01/16/19 01/16 16:08 01/16/19 16:08 Syndicate	Mirati Therapeutics TBA Spot Secondary; price range $50.90-$62.00 » JPMorgan, Citi, Cowen,… JPMorgan, Citi, Cowen, Barclays and Credit Suisse are acting as joint book running managers for the offering. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	17 Jan

MRTX Mirati Therapeutics $62.55 -2.29 (-3.53%) 16:01 01/16/19 01/16 16:01 01/16/19 16:01 Syndicate	Mirati Therapeutics files to sell $75M in common stock » J.P. Morgan Securities… J.P. Morgan Securities LLC, Citigroup Global Markets Inc., Cowen and Company, LLC, Barclays Capital Inc. and Credit Suisse Securities (USA) LLC are acting as joint book-running managers in the offering. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
MRTX Mirati Therapeutics $64.84 1.12 (1.76%) 07:21 01/16/19 01/16 07:21 01/16/19 07:21 Recommendations	Mirati Therapeutics analyst commentary at Oppenheimer » Mirati Therapeutics price… Mirati Therapeutics price target raised to $65 from $57 at Oppenheimer. Oppenheimer analyst Leah Rush Cann raised her price target for Mirati Therapeutics to $65 from $57 after the company announced that it has dosed the first patient in a phase I/II study of MRTX849, in line with prior guidance. The analyst notes that the initiation of this study, along with recent encouraging data from the first preclinical results for this KRAS G12C inhibitor, supports her outlook. She reiterates an Outperform rating on the shares. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial

Over a month ago
MRTX Mirati Therapeutics $64.84 1.12 (1.76%) 16:23 01/15/19 01/15 16:23 01/15/19 16:23 Hot Stocks	Mirati Therapeutics doses first patient in Phase 1/2 MRTX849 clinical trial » Mirati Therapeutics… Mirati Therapeutics announced that it has dosed the first patient in a Phase 1/2 clinical trial of MRTX849, an investigational KRAS G12C inhibitor for patients with advanced solid tumors that harbor KRAS G12C mutations. Mirati's Phase 1/2 clinical trial will evaluate MRTX849 as a single agent in patients with advanced solid tumors that harbor KRAS G12C mutations. The Phase 1 dose escalation phase of the trial will assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of MRTX849 in patients with molecularly-identified KRAS G12C-positive advanced solid tumors. A dose expansion phase is planned to follow the selection of a recommended Phase 2 dose. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
LJPC La Jolla $6.50 0.245 (3.92%) , MDT Medtronic $86.45 1.675 (1.98%) … 14:07 01/15/19 01/15 14:07 01/15/19 14:07 On The Fly	Fly Insider: La Jolla, Landec among week's notable executive stock buys » Welcome to "Fly Insider,"… Open Full Text LJPC La Jolla $6.50 0.245 (3.92%) MDT Medtronic $86.45 1.675 (1.98%) LNDC Landec $11.61 -0.24 (-2.03%) HDS HD Supply $38.70 0.89 (2.35%) MRTX Mirati Therapeutics $65.05 1.33 (2.09%) PRTS U.S. Auto Parts $1.04 -0.01 (-0.95%) SMTC Semtech $51.95 1.05 (2.06%) AMED Amedisys $125.00 7.36 (6.26%) ACOR Acorda Therapeutics $16.52 0.07 (0.43%) BBSI Barrett Business $58.18 0.17 (0.29%) CTRA Contura Energy $62.77 -0.48 (-0.76%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	15 Jan 16 Jan 17 Jan 22 Jan 27 Jan 18 May 28 May
LOXO Loxo Oncology $232.72 92.9 (66.44%) , LLY Eli Lilly $115.25 0.6 (0.52%) … 07:43 01/08/19 01/08 07:43 01/08/19 07:43 Downgrade	Loxo Oncology, Eli Lilly, Mirati Therapeutics rating change at Citi » Loxo Oncology downgraded… Loxo Oncology downgraded to Neutral from Buy at Citi. Citi analyst Yigal Nochomovitz downgraded Loxo Oncology (LOXO) to Neutral saying the company is unlikely to receive a competing takeover bid. The analyst raised his price target for the shares to $235 from $201 to reflect the takeover agreement by Eli Lilly (LLY). He believes Mirati Therapeutics (MRTX) is another potential takeover candidate in the oncology space. LOXO Loxo Oncology $232.72 92.9 (66.44%) LLY Eli Lilly $115.25 0.6 (0.52%) MRTX Mirati Therapeutics $48.29 3.35 (7.45%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	08 Jan 14 Jan 28 Jan 18 May

Get Full Fly Access

Breaking market intelligence sent straight to you: Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.

Up-to-date information on important industry events: Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.

News focused on the companies in your portfolio: Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.

14 Day Free Trial